908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced that on June 1, 2026, the Compensation Committee of its Board of Directors granted options to four new non-executive employees to purchase an aggregate of 179,912 shares of 908 Devices’ common stock. The options were granted as a material inducement to employment with 908 Devices Inc. in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the 908 Devices Inc. 2026 Inducement Plan (the “Plan”).

The inducement stock option has an exercise price of $8.63 per share, which is equal to the closing price of 908 Devices’ common stock on the grant date of June 1, 2026. The inducement stock option vests over four years with 25% of the shares vesting on the first anniversary of the grant date, and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service through each applicable vesting date. The foregoing inducement awards are subject to the terms and conditions of the Plan, and the terms and conditions of the applicable award agreements covering the grant.

About 908 Devices
908 Devices is revolutionizing chemical analysis with its simple handheld devices, addressing life-altering applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers in vital health, safety and defense tech applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure, and global security threats. The Company designs and manufactures innovative products that bring together the power of complementary analytical technologies, software automation, and machine learning. For more information, visit 908devices.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260602174982/en/